Friday, May 02, 2025 3:55:34 PM
Cheers, badgerkid. I have no ulterior motives with the way I'm phrasing my questions and with my very limited understanding of medical science, theres no way I'm questioning their treatments.
However high revenue, the market seems to be questioning profitability and number of treatments, from what I've read. This is why I was asking whether you considered it Q2 earnings to be better in terms of both profitability, number of treatments and revenue.
Just trying to gather information to make an informed decision. All the best.
However high revenue, the market seems to be questioning profitability and number of treatments, from what I've read. This is why I was asking whether you considered it Q2 earnings to be better in terms of both profitability, number of treatments and revenue.
Just trying to gather information to make an informed decision. All the best.
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 10:00:18 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 02:35:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 01:00:40 PM
- Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
